However, the effects of the GC treatment were completely reversed by depletion of gut bacteria, and its effects were also lost or reduced in FXR-knockout mice, indicating that regulation of the gut microbiota and bile acid signaling by GC is required for its anti-NASH activity in vivo. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.